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en inglés. En 57.1% de los estudios, CVRS era un resultado secundario. Tres estudios 
fueron ﬁnanciados por laboratorios farmacéuticos. De los 14 estudios, 4 eran trans-
versales, 4 pre-post, 3 de cohortes y 3 ciegos controlados aleatorizados. En cuanto a 
la calidad del reporte, 64.3% de los estudios utilizaban un instrumento previamente 
validado. La mayoría de los estudios (42.9%) tenían un tamaño de muestra pequeño. 
En sólo 7.1% de los artículos se indicó el tratamiento de los datos perdidos y en 28.6% 
de los artículos se justiﬁcó la selección del instrumento utilizado. CONCLUSIONES: 
Existen pocos estudios publicados que evalúan calidad de vida en Venezuela. La 
mayoría de los estudios utilizan instrumentos diseñados y validados previamente. 
La calidad de los reportes de los estudios de calidad de vida en Venezuela debe 
mejorarse.
PMC4
METHODS: FOR ACHIEVING AND MAINTAINING ADEQUATE STUDY 
SUBJECT PARTICIPATION FOR A MULTI-SITE TIME-SERIES TRIAL
Schoenberger C
Health Analytics, LLC, Columbia, MD, USA
OBJECTIVES: We sought to collect data from a national sample of adults in the 
United States seeking opioid dependence treatment in an outpatient setting. METHODS: 
From among a pool of several thousand physicians listed on a national registry, 
we secured agreements with more than 450 practices to invite their patients to join 
the study. Within three months, we successfully enrolled more than 2000 patients 
through their private physicians into the study. Subjects were required to complete a 
10–15 minute baseline telephonic interview and four additional 15–30 minute tele-
phonic interviews throughout the six month study. A variety of methods were used 
to maximize study enrollment and to retain subjects over the course of six months. 
Coordination of multiple patient and physician touch points was required. Not only 
were physicians asked to attend training and distribute study materials to patients, 
they were also asked to collect informed consent forms from patients. Because inclusion 
criteria dictated that patients must be new to treatment for opioid dependence, 
collection of baseline data had to coincide with treatment start. It was critical that 
any patients interested in joining the study and who provided informed consent be 
contacted immediately so that baseline data could be gathered. Techniques for patient 
engagement included remuneration for completion of each telephonic survey in addition 
to an incentive for enrollment. Baseline and follow-up interviews were scheduled 
according to subjects’ preferences. Patients also received study updates in the mail and 
through their personal physicians. RESULTS: Over the course of 6 months, the subject 
retention rate is at least 70%. We attribute this to a number of strategies, especially 
an efﬁcient study enrollment process, well-managed study administration, and consis-
tent communications with both patients and physicians. CONCLUSIONS: Researchers 
recruiting subjects from a general, treatment-seeking population can achieve sufﬁcient 
study retention by employing these straightforward methods.
MENTAL HEALTH – Clinical Outcomes Studies
PMH1
META-ANALYSIS OF CLINICAL OUTCOMES FROM GUIDELINE-
RECOMMENDED PHARMACOTHERAPIES FOR GENERALIZED ANXIETY 
DISORDER (GAD)
Bereza BG, Machado M, Einarson TR
University of Toronto, Toronto, ON, Canada
OBJECTIVES: The Canadian Psychiatric Association (CPA) treatment guidelines for 
generalized anxiety disorder (GAD) were developed using evidence-based criteria. CPA 
recommends: selective serotonin reuptake inhibitors (SSRIs) or serotonin norepineph-
rine reuptake inhibitors (SNRIs) as 1st line; benzodiazepines, bupropion, buspirone, 
pregabalin, and imipramine as 2nd line; and hyroxyzine, mirtazapine, trazadone as 
3rd line treatments including adjunctive olanzapine or risperidone for treatment-resis-
tant patients. A comprehensive quantitative synthesis of guideline-recommended drug 
therapies for GAD has not been located. The objective of the study was to quantify 
the rates of clinical outcomes of CPA guideline-recommended pharmacotherapies by 
line treatment. METHODS: Evidence from randomized clinical trials cited by the CPA 
and (original research) from meta-analytic evidence were included for review. Pooled 
analyses, duplicates, inappropriate condition, and studies with non-extractable data 
were excluded. Response, remission rates, and baseline, endpoint or mean reductions 
scores of the Hamilton Rating Scale for Anxiety (HAM-A) were extracted. Review 
Manager-5 software (Cochrane Collaboration 2008), with ﬁxed effects model using 
inverse variance weighting, was used to pool results. RESULTS: First line: 36 studies 
included, 21 excluded [pooled-analysis(4) duplicate(14), non-extractable(1), not pub-
lished(1); inappropriate condition(1)], 2nd line: 67 included, 34 excluded [pooled-
analysis(2) duplicate(30) non-extractable(2)], 3rd line: 7 studies included, 0 excluded. 
Mean HAM-A at baseline for 1st line: 24.8 (SD  1.94, N  2594), 2nd line: 25.7 
(SD  2.08, N  2592), 3rd line: 23.4 (SD  3.54, N  274). Mean HAM-A score 
reductions were: 1st line: 13.48 [CI95% 14.33, 12.63, N  1990], 2nd line: 12.19 
[CI95% 12.38, 12.00, N  2046], 3rd line: 12.31 [CI95% 12.96, 11.67, N  
238]. Summary remission rates were: 1st line: 39.7% [CI95% 35.2–44.1%, N  1502], 
2nd line: no pooled results, 3rd line: 35.7% [CI95% 23.1–48.2%, N  56]. Summary 
response rates were 1st line: 67.7% [CI95% 64.1–71.4%, N  2311], 2nd line: 54.5% 
[CI95% 48.0–61.1%, N  1409], 3rd line: 54.9% [CI95% 39.7–70.2%, N  242]. 
CONCLUSIONS: Summary results overlapped substantially; no statistical conclusion 
could be drawn as to which line of therapy was clinically superior.
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SCHIZOPHRENIA MODELING: FACTORS ASSOCIATED WITH THE RISK 
OF BEING IN A SPECIFIC DISEASE STATE
Dragomir A1, Joober R2, Tarride JE3, Angers JF4, Rouleau G4, Drapeau P4, Perreault S5
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OBJECTIVES: We are proposing a research project aimed at better understanding the 
factors associated with speciﬁc disease states associated with schizophrenia. 
METHODS: The model was based on data from RAMQ and Med-Echo databases. 
A total of 12,754 newly diagnosed patients with schizophrenia patients were identiﬁed 
between 1998 and 2006, aged between 0 and 60. Six discrete disease states were 
deﬁned within the model (ﬁrst episode—FE, low dependency state—LDS, high depen-
dency state—HDS, Stable, Well and Death) and patients’ movements between these 
disease states enabled 17 risks to be identiﬁed. To evaluate factors associated to the 
risk of being in each disease state, we constructed 6 risk functions based on Cox pro-
portional hazard analysis for competing risks. The risk factors were modeled including 
age, gender, social assistance status, severity of schizophrenia, depression, anxiolytic 
drugs use and other mental disorders. RESULTS: After the FE of schizophrenia, 
69.8% of patients transitioned to LDS, 11.2% to HDS, 1% to the death state and 
18% into the Well state. Being male (HR: 0.93, 95% CI: 0.89–0.97) or older (HR: 
0.94, 95% CI: 0.91–0.96) was associated with a decreasing risk of moving to LDS 
after being FE. In contrast, being on social assistance, depressed, using anxiolytic drugs 
or being diagnosed with other mental disorders were associated with an increased risk 
of being in a LDS after a FE, ranging from 1.11 to 1.55 folds. The factors associated 
with the risk of being in HDS or Death state after a FE were also estimated.CONCLU-
SIONS: Based on these risk functions, we estimate individual transition probabilities 
that will be used in the ﬁrst Canadian model of schizophrenia incorporating transition 
probabilities adjusted for individual risk factors proﬁles using Canadian data.
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FACTORS THAT PREDICT EARLY TREATMENT FAILURE AMONG 
PATIENTS IN OUTPATIENT TREATMENT FOR OPIOID DEPENDENCE
Ruetsch C
Health Analytics, LLC, Columbia, MD, USA
OBJECTIVES: Practice guidelines for treatment of opioid dependence released in Brazil 
recommend psychosocial treatment such as education and cognitive behavioral therapy 
as a core component of an overall treatment strategy. The purpose of this study was 
to investigate outcome differences between individuals in outpatient treatment for 
opioid dependence who received medication replacement therapy in conjunction with 
a formal psychosocial support program compared with those who received medication 
replacement therapy alone. In particular, we wished to understand whether or not and 
the extent to which adjunctive psychosocial support contributes to reducing early 
treatment failure for opioid dependence. METHODS: A quasi-experimental design 
was employed to randomly assign patients seeking treatment for opioid dependence 
to cases (standard treatment plus psychosocial support program) or controls (standard 
care alone). Data sources included patient self-report and administrative health care 
utilization claims. Collection of baseline measures coincided with treatment start with 
subsequent follow-up measures gathered at 1, 2, 3, and 6 months post baseline. More 
than 1500 subjects across the United States participated in the study. Primary endpoints 
include compliance and adherence to opioid dependence treatment, health care service 
utilization, psychosocial functioning, and addiction symptoms. RESULTS: Compared 
to controls, patients in outpatient treatment for opioid dependence who received 
additional patient support services like addiction education, treatment information, 
and assistance with locating other recovery resources, were less likely to experience 
early treatment withdrawal. CONCLUSIONS: This study demonstrates that when 
offered in conjunction with medication replacement therapy for opioid dependence, a 
formal psychosocial patient support program leads to longer periods of treatment 
retention and lower rates of relapse. In countries like Brazil where ofﬁce-based opioid 
replacement therapy is the ﬁrst-line treatment approach, additional patient support 
services can help reduce recurring relapse. This study has broad implications for com-
munities affected by the morbidity and mortality associated with opioid abuse.
MENTAL HEALTH – Cost Studies
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COSTS AND CONSEQUENCES FOR METABOLIC SYNDROME,  
DIABETES AND CORONARY HEART DISEASE (CHD) RISK AMONG 
SCHIZOPHRENIA PATIENTS TREATED WITH ARIPIPRAZOLE VERSUS 
OLANZAPINE IN BRAZIL
Litalien G1, Nita M2, Golçalves E2, Rached R2
1Bristol-Myers Squibb Pharmaceutical, Wallingford, CT, USA, 2Bristol-Myers Squibb S/A,  
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OBJECTIVES: Atypical antipsychotic medications have been shown to increase dia-
betes and CHD risk in patients by exacerbating lipid, weight, and glucose risk factors 
comprising the metabolic syndrome. We studied in a cost-consequence analysis the 
events and costs associated with the use of olanzapine versus aripiprazole from a 
double blind, 16 week randomized trial of schizophrenia patients. METHODS: A total 
of 173 overweight patients (body mass index „d 27 kglm2) with schizophrenia or 
schizoaffective disorder (previously treated with olanzapina) were randomized to 
treatment with aripiprazole or continued olanzapine monotherapy for 16-weeks 
Rio Abstracts A521
following a 2-week, open-label, observation period during which subjects continued 
to receive olanzapine. The rate of ATP-I Il metabolic syndrome, and the long term 
risk for diabetes and CHD was estimated and compared between arms. Brazilian costs 
and health resource estimates were applied to each event. Established risk functions 
were used to estimate diabetes and CHD risk. RESULTS: Among all patients, the 
baseline rate of metabolic syndrome was 89%. At 16 weeks, 80.3% of olanzapine 
versus 60% of aripiprazole patients exhibited metabolic syndrome (RR: 0.75; 95%Cl: 
0.61–0.92, p  0.006). Diabetes risk increased by 1.3% (aripiprazole patients) and 
6.4% (olanzapine patients), risk difference  5.1 %. CHD risk decreased by 0.6% 
(aripiprazole patients) and increased by 0.3% (olanzapine patients), risk difference  
0.9%. Among 1000 patients, treatment with aripiprazole versus olanzapine would 
avert 203 metabolic syndrome events, 51 diabetes events, and 9 CHD events at a cost 
of R$1,520.63, R$1.856, and R$4,122.31, per event avoided respectively. The total 
cost difference was R$440,442. Risk differences were driven primarily by signiﬁcant 
weight and lipid changes between agents, favoring aripiprazole. CONCLUSIONS: 
Antipsychotic-related metabolic adverse events and the consequent risk of diabetes 
and CHD can add substantively to health care costs among patients with schizophre-
nia in Brazil. Health care providers should consider these risks in the selection of 
appropriate antipsychotic agents.
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COST-EFFECTIVENESS OF RISPERIDONE LONG-ACTING INJECTABLE 
VERSUS QUETIAPINE IN SCHIZOPHRENIC PATIENTS
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OBJECTIVES: To assess the cost-effectiveness of treatment of schizophrenia with 
Risperidone long acting injectable (RLAI) in comparison with oral Quetiapine using 
an economic model. METHODS: A decision-tree model was built using a treatment 
algorithm simulating the Brazilian Public Health System and applying the rehospital-
ization rates extracted from a 2-year head-to-head study which compared RLAI and 
oral quetiapine. Cost data were extracted from an analysis of direct cost of hospitaliza-
tion in a Brazilian public mental health hospital. As usual in the Public Health System, 
patients considered in this model had previously used Oral Risperidone and were 
elegible to use other second-generation antipsychotics, as well as switch to others. 
RESULTS: In the head-to-head comparison, patients treated with RLAI had a rehos-
pitalization rate of 33.1%, while patients treated with Quetiapine had a rehospitaliza-
tion rate of 16.5% (p  0.0001). In a hypothetical cohort of 1000 patients followed 
for two years, the number of hospital days was 3.3 higher in the Quetiapine group, 
and the number of patients requiring hospitalization in the Quetiapine group was 1.8 
higher, which represent 139 patients without hospitalization in the RLAI group in the 
same period. Mean number of days at hospital was lower with RLAI (32 days) than 
with Quetiapine (64 days). RLAI was the treatment with lower direct cost, generating 
an annual saving of R$1040.00 per patient in the Public System. CONCLUSIONS: 
In comparison with Quetiapine, RLAI is cost saving, due to lower rehospitalization 
rates.
PMH10
ANÁLISE DE CUSTO EFETIVIDADE DOS ANTIPSICÓTICOS  
ATÍPICOS NO TRATAMENTO DA ESQUIZOFRENIA COM BASE NO 
NNT(NÚMERO NECESSÁRIO TRATAR)
Pereira M, Duchesne I
Janssen-Cilag, São Paulo, Brazil
OBJETIVOS: A Medicina Baseada em Evidências é importante por fornecer indica-
dores que avaliam a eﬁcácia de tratamento em perceptiva mais prática, como o número 
necessário tratar (NNT), que representa o número de pacientes que é necessário tratar 
para obter um desfecho favorável, comparado a taxa de sucesso do grupo controle. 
O NNT é útil na tomada de decisão, pois demonstra pelo impacto orçamentário não 
só o “custo de sucesso” (custo efetividade) mas tambem o “custo de desperdício”. Um 
NNT de 7.0 signiﬁca que é necessário tratar 7 pacientes para obteção de um desfecho 
favorável, signiﬁcando que 6 pacientes foram tratados sem sucesso. O Sistema de 
Saúde Público (SUS) do Brasil apresenta atualmente altos custos no tratamento da 
esquizofrenia. Paliperidona é um novo antipsicótico atípico oral de liberação pro-
longada e dose diária única.O objetivo é demonstrar por análise de custo efetividade 
baseada em NNT,o custo para obtenção de sucesso clínico, para antipsicóticos atípicos 
(paliperidona, olanzapina, quetiapina, ziprazidona, aripiprazol). MÉTODOS: Os 
valores de NNT utilizados para olanzapina, ziprasidona, quetiapina e aripiprazol 
foram obtidos de revisões sistemáticas da Cochrane. O NNT da paliperidona foi reti-
rado da bula. Para cálculo dos custos diários de tratamento foi utilizada a Dose Diária 
Deﬁnida (DDD) e preços retirados da revista indexada. RESULTADOS: Os valores 
de NNT encontrados foram: 7.0 olanzapina, 5.0 aripiprazol, 7.0 ziprasidona e 8.0 
quetiapina. Para paliperidona, o NNT obtido foi 3.87. Os custos para obter um 
sucesso clínico foram, R$3,851 (olanzapina), R$ 2,747 (aripiprazol), R$2,423 
(ziprasidona), R$6,115 (quetiapina) e R$2,003 (paliperidona). CONCLUSÕES: 
 Paliperidona demonstrou o melhor NNT e o menor “custo de sucesso clinico” com-
parada aos outros atípicos. Assim, a escolha do tratamento com a paliperidona torna-
se uma opção eﬁciente.
PMH6
COSTO-EFECTIVIDAD DE OCHO MEDICAMENTOS ANTIPSICÓTICOS 
EN COLOMBIA
Alandete J1, Rosselli D2
1Janssen-Cilag Colombia, Bogotá, Colombia, 2Independiente, Bogotá, Colombia
OBJECTIVOS: Evaluar la costo-utilidad de los principales medicamentos antipsicóti-
cos en el contexto colombiano. METODOLOGÍAS: Con un modelo de árbol de 
decisión (horizonte temporal de un año, perspectiva de tercero pagador), se simulan 
ocho medicamentos antipsicóticos: haloperidol y siete atípicos (aripiprazol, clozapina, 
olanzapina, paliperidona, quetiapina, risperidona y ziprasidona). Se utilizaron datos 
de efectividad y adherencia del estudio CATIE, los valores de haloperidol, clozapina 
y paliperidona se obtuvieron de estudios clínicos y panel de expertos locales. Los 
eventos adversos se obtuvieron de estudios clínicos. Los costos directos sanitarios 
corresponden al valor de facturación de prestadores de servicios de salud locales y la 
calidad de vida en QALY se obtuvo del registro de utilidades de Tufts. Tasa de cambio 
US$1  Col$2391. RESULTADOS: El costo de atención en salud anual promedio fue: 
haloperidol US$1724, paliperidona US$2263, risperidona US$2546, clozapina 
US$2963, ziprasidona US$2998, quetiapina US$3500, olanzapina US$3645, y aripip-
razol US$3890. Comparado con haloperidol, la menor razón incremental de costo-
utilidad corresponde a paliperidona (US$25.8K / QALY). En los otros atípicos, ésta 
varía entre US$54K (risperidona) y US$238K (aripiprazol). Estos valores estarían 
magniﬁcados por las pequeñas diferencias en utilidades (entre 0.63 QALY para halo-
peridol y 0.65 QALY para olanzapina y paliperidona). Considerando lo anterior, cal-
culamos el beneﬁcio neto. Con una disponibilidad a pagar de US$25K por QALY, 
haloperidol y paliperidona generarían un beneﬁcio similar (US$14.1K) que es mayor 
al de cualquier otro atípico (entre US$12.7K con olanzapina y US$13.7K con risperi-
dona). CONCLUSIONES: Haloperidol sigue siendo el antipsicótico más costo- 
efectivo en el mercado. En este modelo, que minimiza diferencias en efectividad, el 
único antipsicótico costo-efectivo comparable con haloperidol es la paliperidona. Un 
trabajo posterior incluirá costos indirectos y un seguimiento mayor. Estos resultados 
sugieren que paliperidona sería el medicamento de elección al prescribir un antip-
sicótico atípico oral.
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HEALTH CARE RESOURCE UTILIZATION IN THE TREATMENT OF 
DEPRESSION IN MEXICO
Rivas R, Zapata L
Guia Mark, Mexico, DF, Mexico
OBJECTIVES: Depression is one of the most frequent mental health ailments. It has 
been estimated that by year 2020, it will be the worldwide second cause for the loss 
of healthy life years and the ﬁrst cause in developed countries. In Mexico, the preva-
lence of major depression is estimated from 7% to 12%. However there is not infor-
mation regarding health care resources use in Mexico for this pathology. This, study’s 
objective is to document the health care resource use for depression treatment in 
Mexico. METHODS: Twenty one mental health specialists from a public health 
institution were asked to answer a questionary. Additionally, modiﬁed Delphi method 
was applied with eight specialist to further analyze some of the topics. A database 
was created from the answers and a statistic analysis was performed. RESULTS: Sixty 
percent of the ambulatory patients of the psiquatric area turn to the specialist due to 
depression and from these 40% due to major depression. Eighteen percent of the 
depression patients require hospitalization and, in average, they stay in the hospital 
25 days. Approximately 39% of the patients with major depression become handi-
capped 3 periods of 14 days during the treatment. The average prescription time for 
the anti-depressive drugs is 11.3 months; however, the specialist reported that the 
prescription time could be from 4 to 27 months. CONCLUSIONS: This study provides 
base line information regarding the use of health care resources use in the treatment 
of depressed patients in Mexico. Further evaluations of the disease burden in the 
country should be performed.
MENTAL HEALTH – Patient-Reported Outcomes Studies
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FACTORES ASOCIADOS AL INCUMPLIMIENTO DE TRATAMIENTOS 
CON ANTIDEPRESIVOS EN SANTIAGO, CHILE
Jirón M1, Escobar L1, Arriagada L2, Orellana S1, Castro A2, Sandoval R1, Salazar N1
1Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile, 
2Hospital Clínico de la Universidad de Chile, Santiago, Chile
OBJECTIVOS: Identiﬁcar los factores asociados al incumplimiento de tratamientos 
con antidepresivos (AD) en Santiago, Chile. METODOLOGÍAS: Mediante un estudio 
transversal se entrevistó en hogares a una muestra representativa y probabilística de 
1000 personas q 15 años en Santiago, Chile. Los datos se analizaron a través de 
estadística descriptiva y regresiones logísticas con STATA 8.0. RESULTADOS: De los 
171(17.1%)sujetos que declararon haber consumido alguna vez en su vida AD, el 
52.4% declaró ser incumplidor para dosis, tiempo recomendado de uso y/o ambas 
(33.2% para dosis y 38.3% para tiempo de uso). Al estudiar el incumplimiento al 
tiempo recomendado de uso, se observaron diferencias signiﬁcativas en Grupo Socio-
económico (GSE) bajo que presentó 5.3 veces más riesgo de incumplimiento que GSE 
alto (OR  5.3; IC95% 1.51–18.40; p  0.009). La condición de mujer con GSE 
medio-alto y bajo presentó más riesgo de incumplimiento que mujer de GSE alto (OR 
 3.95; IC95% 1.29–12.15; p  0.016) y (OR  4.3; IC95% 1.11–16.52; p  0.035), 
respectivamente. Además, al estudiar el incumplimiento a la dosis prescrita se observó 
